Cerevel Therapeutics Holdings News

Cerevel Therapeutics Gains After AbbVie Says Making Good Progress With FTC

Seeking AlphaJun 12 11:30 ET

Catalyst Watch: Apple's WWDC, Tesla's Annual Meeting, Fed's Dot Plot, and GameStop Volatility

Seeking AlphaJun 7 15:00 ET

Unusual Options Activity: TMUS, CERE and Others Attract Market Bets, TMUS V/OI Ratio Reaches 161.3

EST Jun 6th Afternoon Delivery - In the last two hours of trading, 7 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.

moomoo NewsJun 6 13:30 ET

Cerevel Therapeutics Holdings(CERE.US) Director Sells US$2.03 Million in Common Stock

$Cerevel Therapeutics Holdings(CERE.US)$ Director COLES N ANTHONY sold 50,000 shares of common stock on Jun 3, 2024 at an average price of $40.6104 for a total value of $2.03 million.Source: Announcem

moomoo NewsJun 5 16:45 ET

10 Health Care Stocks Whale Activity In Today's Session

This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan

BenzingaJun 4 13:35 ET

Form 144 | Cerevel Therapeutics Holdings(CERE.US) Director Proposes to Sell 2.04 Million in Common Stocks

SEC FILLINGS DISCLOSED/ Jun 3, $Cerevel Therapeutics Holdings(CERE.US)$ Director NEAVELLE ANTHONY COLES intends to sell 50,000 shares of its common stock on Jun 3, with a total market value of approxi

moomoo NewsJun 3 17:02 ET

Calling All Cerevel Therapeutics Holdings, Inc. (CERE) Investors: Contact Bronstein, Gewirtz &...

Stockhouse May 30 12:00 ET

Calling All Cerevel Therapeutics Holdings, Inc. (CERE) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses

Business WireMay 29 13:04 ET

Cerevel Therapeutics Holdings(CERE.US) Director Sells US$2.11 Million in Common Stock

$Cerevel Therapeutics Holdings(CERE.US)$ Director COLES N ANTHONY sold 50,000 shares of common stock on May 10, 2024 at an average price of $42.1025 for a total value of $2.11 million.Source: Announce

moomoo NewsMay 14 17:59 ET

Cerevel Therapeutics Holdings Insider Sold Shares Worth $2,105,125, According to a Recent SEC Filing

N Anthony Coles, Director, on May 10, 2024, sold 50,000 shares in Cerevel Therapeutics Holdings (CERE) for $2,105,125. Following the Form 4 filing with the SEC, Coles has control over a total of 15,63

MT NewswiresMay 14 17:23 ET

Form 144 | Cerevel Therapeutics Holdings(CERE.US) Director Proposes to Sell 2.12 Million in Common Stocks

SEC FILLINGS DISCLOSED/ May 10, $Cerevel Therapeutics Holdings(CERE.US)$ Director NEAVELLE ANTHONY COLES intends to sell 50,000 shares of its common stock on May 10, with a total market value of appro

moomoo NewsMay 10 16:30 ET

Cerevel Therapeutics Holdings | 10-Q: Quarterly report

SEC announcementMay 8 17:08 ET · Announcements

Cerevel Therapeutics Holdings Insiders Placed Bullish Bets Worth US$2.51m

Quite a few insiders have dramatically grown their holdings in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) over the past 12 months. An insider's optimism about the company's prospects is a posit

Simply Wall StApr 30 08:04 ET

Cerevel (CERE.US), acquired by ABBV.US (ABBV.US), achieves key targets for advanced Parkinson's disease drugs

Cerevel Therapeutics announced Thursday that its once-a-day oral drug candidate for Parkinson's disease, tavapadon, has achieved key goals in a key phase 3 trial as a combination therapy.

Zhitong FinanceApr 18 09:25 ET

Sector Update: Health Care Stocks Mixed Pre-Bell Thursday

Health care stocks were mixed pre-bell Thursday, with the iShares Biotechnology ETF (IBB) down 0.1% and the Health Care Select Sector SPDR Fund (XLV) 0.4% higher. Elevance Health (ELV) stock was up mo

MT NewswiresApr 18 09:12 ET

AbbVie Buyout Cerevel Posts Late-stage Win for Parkinson's Disease Drug

Seeking AlphaApr 18 07:00 ET

Express News | Cerevel Therapeutics' Topline Results From Phase 3 TEMPO-3 Trial For Tavapadon For Parkinson's Disease, Met Primary Endpoint, Demonstrating Statistically Significant Increase In Total "On" Time Without Troublesome Dyskinesia Vs. Placebo

Moomoo 24/7Apr 18 06:34 ET

Express News | Cerevel Therapeutics Holdings Inc - Tavapadon Was Generally Well Tolerated

Moomoo 24/7Apr 18 06:30 ET

Express News | Cerevel: Statistically Significant Reduction in "off" Time, Key Secondary Endpoint, Observed for Tavapadon Treatment Arm

Moomoo 24/7Apr 18 06:30 ET

Express News | Cerevel Therapeutics Holdings Inc - Results From Tavapadon Phase 3 Monotherapy Trials (Tempo-1 and Tempo-2) Are Expected in Second Half of 2024

Moomoo 24/7Apr 18 06:30 ET